Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Gross Profit: 2014-2025

Historic Gross Profit for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Sep 2025 value amounting to $70.6 million.

  • Viridian Therapeutics, Inc.\DE's Gross Profit rose 81958.14% to $70.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $70.8 million, marking a year-over-year increase of 23340.07%. This contributed to the annual value of $302,000 for FY2024, which is 3.82% down from last year.
  • Viridian Therapeutics, Inc.\DE's Gross Profit amounted to $70.6 million in Q3 2025, which was up 93,993.33% from $75,000 recorded in Q2 2025.
  • In the past 5 years, Viridian Therapeutics, Inc.\DE's Gross Profit ranged from a high of $70.6 million in Q3 2025 and a low of $72,000 during Q2 2023.
  • In the last 3 years, Viridian Therapeutics, Inc.\DE's Gross Profit had a median value of $72,000 in 2025 and averaged $6.5 million.
  • Its Gross Profit has fluctuated over the past 5 years, first tumbled by 93.97% in 2023, then soared by 81,958.14% in 2025.
  • Viridian Therapeutics, Inc.\DE's Gross Profit (Quarterly) stood at $214,000 in 2021, then slumped by 50.93% to $105,000 in 2022, then tumbled by 31.43% to $72,000 in 2023, then remained steady at $72,000 in 2024, then surged by 81,958.14% to $70.6 million in 2025.
  • Its Gross Profit stands at $70.6 million for Q3 2025, versus $75,000 for Q2 2025 and $72,000 for Q1 2025.